Research
Cagrilintide Peptide Structure
| Molecular formula: | C194H312N54O59S2 |
| Molecular weight: |
4409.01 g/mol
|
| PubChem SID: |
433770923 |
| CAS Number: | 1415456-99-3 |
| Research Applications: |
|
Cagrilintide Research Overview
Cagrilintide is a novel, long-acting acylated amylin analogue that functions as a non-selective agonist for amylin receptors (AMYR) and the calcitonin G protein-coupled receptor (CTR). Cagrilintide is structurally similar to pramlintide but with key differences, including the lipidation of the N-terminal lysine and substitutions of three amino acids (N14E, V17R, and P37Y). These modifications are designed to improve stability and efficacy. Cagrilintide has shown promise in obesity research by significantly reducing food intake and inducing weight loss [R].
Cagrilintide works by activating amylin receptors, particularly in the homoeostatic and hedonic regions, leading to reduced appetite and increased feelings of fullness. Unlike natural amylin, which has a short half-life and a tendency to form amyloid fibrils, cagrilintide is engineered to have a longer action profile and greater stability [R].
Clinical trials have demonstrated that cagrilintide, both as monotherapy and in combination with the GLP-1 receptor agonist semaglutide (CagriSema), leads to significant weight loss in individuals with overweight and obesity. The combination therapy, CagriSema, has also shown improved glycemic control and greater weight loss compared to semaglutide alone in patients with type 2 diabetes [R, R, R].
